Which solid tumor types is Adagrasib suitable for?

Adagrasib is an oral KRAS G12C mutation-selective inhibitor specifically developed for patients with solid tumors carrying KRAS G12C gene mutations. KRAS G12CMutation is a common driver gene mutation in a variety of solid tumors, especially in tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer. Adagrasib targets this mutation and blocks tumor cell proliferation signals, thereby exerting anti-tumor effects.

The main indication for adagrasib is non-small cell lung cancer (NSCLC), especially patients carrying KRAS G12C mutations. In the past, these patients lacked effective targeted treatment options, and traditional chemotherapy and immunotherapy had limited effectiveness. Clinical trials have shown that adagrasib can significantly prolong the progression-free survival and overall survival of patients, improve the quality of life, and become one of the important treatment options for such patients.

The application of adagrasib in colorectal cancer has also attracted much attention. Although the proportion of KRAS G12C mutations in colorectal cancer is relatively low, adagrasib has demonstrated good anti-tumor activity in patients with this subtype. Combined with other treatments, adagrasib offers new hope for colorectal cancer patients, especially when traditional treatments are ineffective or resistant.

Adagrasib is exploring its potential in other solid tumors carrying KRAS G12C mutations, such as pancreatic cancer, bladder cancer, etc. As more clinical trials are conducted, its scope of indications is expected to be further expanded, bringing precise treatment options to more patients with solid tumors.

In short, adagrasib is mainly suitable for patients with KRAS G12C mutation-positive non-small cell lung cancer and colorectal cancer, and also shows positive research prospects in other tumor types. In the future, with in-depth research and drug optimization, adagrasib is expected to become an important targeted therapy drug for more patients with solid tumors.

Reference materials:https://www.drugs.com/